Combined Poly(Lactide-Co-Glycolide) Microspheres Containing Diphtheria Toxoid for a Single-shot Immunization
To develop a single-shot vaccine containing diphtheria toxoid (DT) with a sufficient immune response, poly(lactide-co-glycolide) (PLGA) microspheres were prepared by water-in-oil-in-water double emulsification and solvent extraction techniques using low or high-molecular-weight PLGA (LMW-MS or HMW-MS). Stearic acid (SA) was introduced to HMW-MS (HMW/SA-MS) as a release modulator. Mean particle sizes (dvs, μm) varied between the prepared microspheres, with LMW-MS, HMW-MS, and HMW/SA-MS having the sizes of 29.83, 110.59, and 69.5 μm, respectively; however, the protein entrapment and loading efficiency did not vary, with values of 15.2–16.8 μg/mg and 61–75%, respectively. LMW-MS showed slower initial release (~ 2 weeks) but faster and higher release of antigen during weeks 3~7 than did HMW-MS. HMW/SA-MS showed rapid initial release followed by a continuous release over an extended period of time (~ 12 weeks). Mixed PLGA microspheres (MIX-MS), a combination of HMW/SA-MS and LMW-MS (1:1), demonstrated a sufficient initial antigen release and a subsequent boost release in a pulsatile manner. Serum antibody levels were measured by ELISA after DT immunization of Balb/c mice, and showed a greater response to MIX-MS than to alum-adsorbed DT (control). A lethal toxin challenge test with MIX-MS (a DT dose of 18 Lf) using Balb/c mice revealed complete protection, indicating a good candidate delivery system for a single-shot immunization.
KEY WORDSPLGA single-shot vaccine diphtheria toxoid stearic acid immunization
This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI17C0710).
- 1.Park JY, Kim MG, Shim G, Oh YK. Lipid-based antigen delivery systems. J Pharm Invest. 2016;46(4):295–304. https://doi.org/10.1007/s40005-016-0246-z.
- 4.Feng L, Qi XR, Zhou XJ, Maitani Y, Wang SC, Jiang Y, et al. Pharmaceutical and immunological evaluation of a single-dose hepatitis B vaccine using PLGA microspheres. J Control Release. 2006;112(1):35–42.Google Scholar
- 6.Yoon MK, Choi YW. Improved antigen delivery systems with PLGA microsphere for a single-step immunization. J Pharm Invest. 2004;34(1):1–14. https://doi.org/10.4333/KPS.2004.34.1.001.
- 7.Kim JH, Choi EH, Park SE, Kim YJ, Jo DS, Kim YK, et al. Recommended immunization schedule for children and adolescents: Immunization Guideline (8th edition) released by the Korean Pediatric Society in 2015. Korean J Pediatr. 2016;59(12):461–5. https://doi.org/10.3345/kjp.2016.59.12.461.CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Baker CJ. Red book atlas of pediatric infectious diseases. 3rd ed. Elk Grove: American Academy of Pediatrics; 2016.Google Scholar
- 10.Rosas JE, Pedraz JL, Hernández RM, Gascón AR, Igartua M, Guzmán F, et al. Remarkably high antibody levels and protection against P. falciparum malaria in Aotus monkeys after a single immunisation of SPf66 encapsulated in PLGA microspheres. Vaccine. 2002;20(13-14):1707–10. https://doi.org/10.1016/S0264-410X(01)00508-4.
- 12.Thomasin C, Corradin G, Men Y, Merkle HP, Gander B. Tetanus toxoid and synthetic malaria antigen containing poly(lactide)/poly(lactide-co-glycolide) microspheres: importance of polymer degradation and antigen release for immune response. J Control Release. 1996;41(1–2):131–45. https://doi.org/10.1016/0168-3659(96)01363-6.CrossRefGoogle Scholar
- 13.Lee HK, Park JH, Kwon KC. Double-walled microparticles for single shot vaccine. J Control Release. 1997;44(2-3):283–93. https://doi.org/10.1016/S0168-3659(96)01534-9.
- 14.Audran R, Peter K, Dannull J, Men Y, Scandella E, Groettrup M, et al. Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro. Vaccine. 2003;21(11):1250–5. https://doi.org/10.1016/S0264-410X(02)00521-2.
- 15.Park Ok, Yu GH, Jung HJ, Mok HJ. Recent studies on micro-/nano-sized biomaterials for cancer immunotherapy. J Pharm Invest. 2017;47(1):11–8. https://doi.org/10.1007/s40005-016-0288-2.
- 16.Raghuvanshi RS, Katare YK, Lalwani K, Ali MM, Singh O, Panda AK. Improved immune response from biodegradable polymer particles entrapping tetanus toxoid by use of different immunization protocol and adjuvants. Int J Pharm. 2002;245(1-2):109–21. https://doi.org/10.1016/S0378-5173(02)00342-3.
- 17.Demento SL, Cui W, Criscione JM, Stern E, Tulipan J, Kaech SM, et al. Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype. Biomaterials. 2012;33(19):4957–64. https://doi.org/10.1016/j.biomaterials.2012.03.041.CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Jeffery H, Davis SS, O’Hagan DT. The preparation and characterization of poly(lactide-co-glycolide) microparticles. II. The entrapment of a model protein using a (water-in-oil)-in-water emulsion solvent evaporation technique. Pharm Res. 1993;10(3):362–8. https://doi.org/10.1023/A:1018980020506.CrossRefPubMedGoogle Scholar
- 21.O’Hagan DT, Jeffery H, Davis SS. The preparation and characterization of poly (lactide-co-glycolide) microspheres: III. Microparticle/polymer degradation rates and the in vitro release of a model protein. Int J Pharm. 1994;103(1):37–45. https://doi.org/10.1016/0378-5173(94)90201-1.CrossRefGoogle Scholar
- 22.Matsuo K, Ishii Y, Quan YS, Kamiyama F, Mukai Y, Yoshioka Y, et al. Transcutaneous vaccination using a hydrogel patch induces effective immune responses to tetanus and diphtheria toxoid in hairless rat. J Control Release. 2011;149(1):15–20. https://doi.org/10.1016/j.jconrel.2010.05.012.CrossRefPubMedGoogle Scholar
- 24.Jung T, Koneberg R, Hungerer KD, Kissel T. Tetanus toxoid microspheres consisting of biodegradable poly(lactide-co-glycolide)- and ABA-triblock-copolymers: immune response in mice. Int J Pharm. 2002;234(1-2):75–90. https://doi.org/10.1016/S0378-5173(01)00957-7.
- 28.Yang YY, Chung TS, Ng NP. Morphology, drug distribution and in vitro release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion solvent extraction/evaporation method. Biomaterials. 2001;22(3):231–41. https://doi.org/10.1016/S0142-9612(00)00178-2.CrossRefPubMedGoogle Scholar
- 29.Reits E, Griekspoor A, Neijssen J, Groothuis T, Jalink K, van Veelen P, et al. Peptide diffusion, protection, and degradation in nuclear and cytoplasmic compartments before antigen presentation by MHC class I. Immunity. 2003;18(1):97–108. https://doi.org/10.1016/S1074-7613(02)00511-3.CrossRefPubMedGoogle Scholar
- 30.Huang X, Brazel CS. On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. J Control Release. 2001;73(2-3):121–36. https://doi.org/10.1016/S0168-3659(01)00248-6.
- 33.Kim HS, Shin TH, Yoon MK, Kang MJ, Lee JH, Choi YW. Effects of non-ionic surfactant on the release of protein drug from poly (dl-lactide-co-glycolide) microspheres. Tissue Eng Regen Med. 2008;5(4):798–803.Google Scholar
- 38.Chu D, Tian J, Liu W, Li Z, Li Y. Poly(lactic-co-glycolic acid) microspheres for the controlled release of huperzine a: in vitro and in vivo studies and the application in the treatment of the impaired memory of mice. Chem Pharm Bull. 2007;55(4):625–8. https://doi.org/10.1248/cpb.55.625.
- 39.Kissel T, Li YX, Volland C, Gorich S, Koneberg R. Parenteral protein delivery systems using biodegradable polyesters of ABA block structure, containing hydrophobic poly(lactide-co-glycolide) A blocks and hydrophilic poly(ethylene oxide) B blocks. J Control Release. 2006;39(2-3):315–26.Google Scholar